NCT03013010 2025-12-08
PREACT
Shanghai Cancer Hospital, China
Phase 3 Completed
Clinical Trials
108 trialsNCT05052723 2025-11-19
Cabozantinib and Pembrolizumab in Metastatic Pancreas
University of Kentucky
Phase 2 Completed
NCT03777813 2025-11-18
ARION
UNICANCER
Phase 2 Completed
NCT06358001 2025-09-22
EchoTip AcuCore Post-Market Clinical Study
Cook Group Incorporated
Completed
NCT02415101 2025-09-03
NeoResII
Karolinska University Hospital
Phase NA Completed
NCT02905578 2025-08-27
A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
University of Iowa
Phase 2 Completed
NCT05678218 2025-08-08
POELH-II
Erasmus Medical Center
Completed
NCT03572283 2025-06-05
Bethanechol Prior to Pancreatic Surgery
Columbia University
Phase EARLY_PHASE1 Completed
NCT03037385 2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2 Completed
NCT02795988 2025-04-16
A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
Imugene Limited
Phase 1/2 Completed
NCT01249352 2025-03-31
NICE
Eurofarma Laboratorios S.A.
Phase 2/3 Completed
NCT05233098 2025-03-06
TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.
Boston Scientific Corporation
Completed
NCT03092518 2025-02-19
Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT04034251 2025-02-03
Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03153410 2025-01-09
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Completed
NCT04989816 2024-11-21
DG-06
AstraZeneca
Phase 2 Completed
NCT01393483 2024-10-28
Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)
Memorial Sloan Kettering Cancer Center
Completed
NCT01404156 2024-08-28
POWERRANGER
CancerCare Manitoba
Phase 2/3 Completed
NCT02112656 2024-08-20
OPTIMA
Imunon
Phase 3 Completed
NCT03861793 2024-03-05
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
Mural Oncology, Inc
Phase 1/2 Completed
NCT02918162 2024-02-15
Perioperative Chemo and Pembrolizumab in Gastric Cancer
Columbia University
Phase 2 Completed
NCT05074472 2024-01-29
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors
ZielBio, Inc.
Phase 1/2 Completed
NCT03415854 2023-12-15
NABPLAGEMD
HonorHealth Research Institute
Phase 2 Completed
NCT05606094 2023-12-15
Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia
Daiichi Sankyo
Completed
NCT02993731 2023-11-15
CanStem111P
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT01726582 2023-08-14
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Medical College of Wisconsin
Phase 2 Completed
NCT04034238 2023-08-01
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04990037 2023-06-29
CAPAFOUR
Cantargia AB
Phase 1 Completed
NCT01964430 2023-06-28
apact
Celgene
Phase 3 Completed
NCT01607905 2023-01-26
Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Karyopharm Therapeutics Inc
Phase 1 Completed
NCT02890069 2023-01-11
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Novartis
Phase 1 Completed
NCT03368196 2022-11-03
DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein
Daiichi Sankyo
Phase 1 Completed
NCT02428270 2022-11-01
A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer
University Health Network, Toronto
Phase 2 Completed
NCT04769414 2022-08-08
Flouro-Gem in Adenocarcinoma of the Pancreas (GEFLUPAN)
Menoufia University
Phase 2 Completed
NCT02347618 2022-07-18
Pilot Study of Short-Course Preoperative Stereotactic Body Radiation Therapy for Resectable Pancreatic Cancer
University of Rochester
Phase NA Completed
NCT02900664 2022-03-29
A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)
Novartis
Phase 1 Completed
NCT03329690 2022-03-18
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]
Daiichi Sankyo
Phase 2 Completed
NCT01077817 2022-02-03
Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)
Organon and Co
Completed
NCT01442649 2022-01-11
Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab
UNICANCER
Phase 2 Completed
NCT01442935 2021-06-18
Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases
UNICANCER
Phase 2 Completed
NCT04669951 2021-06-03
Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Cancer
Rigshospitalet, Denmark
Phase NA Completed
NCT03388047 2021-04-28
MuSE
University of Cambridge
Phase NA Completed
NCT01077999 2021-04-21
Chemoradiation and Panitumumab for Esophageal Cancer
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2 Completed
NCT01217060 2021-04-13
Trimodality Management of T1b Esophageal Cancers
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02048384 2021-04-12
A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT01652976 2021-01-05
FOLFOX-D
University of Florida
Phase 2 Completed
NCT03207724 2020-12-30
OnFX
Cedars-Sinai Medical Center
Phase 1 Completed
NCT01487785 2020-12-19
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
Novartis
Phase 1 Completed
NCT01443065 2020-11-17
MEGA
UNICANCER
Phase 2 Completed
NCT01385956 2020-09-28
SOM 230 and Gemcitabine in Advanced Pancreatic Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed